Provided by Tiger Trade Technology Pte. Ltd.

Benitec Biopharma

12.28
+0.01000.08%
Post-market: 12.520.2400+1.95%19:03 EDT
Volume:149.32K
Turnover:1.84M
Market Cap:420.65M
PE:-11.64
High:12.56
Open:12.22
Low:12.08
Close:12.27
52wk High:17.15
52wk Low:9.85
Shares:34.25M
Float Shares:20.85M
Volume Ratio:0.58
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0553
EPS(LYR):-1.0472
ROE:-33.50%
ROA:-22.40%
PB:2.25
PE(LYR):-11.73

Loading ...

Benitec Biopharma Announces Appointment of Sharon Mates Ph.d. to Its Board of Directors

THOMSON REUTERS
·
Nov 03, 2025

Press Release: Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

Dow Jones
·
Nov 03, 2025

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

GlobeNewswire
·
Nov 03, 2025

Benitec Biopharma’s BB-301 Study: A Potential Game-Changer for OPMD Treatment?

TIPRANKS
·
Oct 28, 2025

Benitec Biopharma Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Oct 15, 2025

Benitec Biopharma’s Strong Financial Position and Promising Clinical Progress Justify Buy Rating

TIPRANKS
·
Sep 25, 2025

Benitec Biopharma Inc. Reports No Revenue for Fiscal Year 2025; Net Loss Widens to $37.9 Million or $1.05 per Share

Reuters
·
Sep 23, 2025

Leerink Partners Reaffirms Their Buy Rating on Benitec Biopharma (BNTC)

TIPRANKS
·
Sep 23, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Sep 23, 2025

Benitec Biopharma Reports 2025 Financial Results and Progress

TIPRANKS
·
Sep 23, 2025

Benitec Biopharma files $200M mixed securities shelf

TIPRANKS
·
Sep 23, 2025

BRIEF-Benitec Biopharma Files For Mixed Shelf Offering Of Up To $200 Million - SEC Filing

Reuters
·
Sep 23, 2025

Benitec Biopharma Q4 EPS $0.00 Beats $(0.33) Estimate

Benzinga
·
Sep 23, 2025

Benitec Biopharma: Enrollment of First Subject Into Cohort 2 of Bb-301 Phase 1B/2a Treatment Study Expected in Q4 2025

THOMSON REUTERS
·
Sep 23, 2025

Press Release: Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

Dow Jones
·
Sep 23, 2025

Benitec Biopharma Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
Sep 22, 2025

Benitec Biopharma price target lowered to $29 from $35 at Oppenheimer

TIPRANKS
·
Sep 16, 2025

BRIEF-Benitec Biopharma Says Financial Statements For Three And Nine Months Ended March 31, 2025 December 31, 2024 Not Reliable - SEC Filing

Reuters
·
Sep 13, 2025

Benitec Biopharma Inc - Financial Statements for Three and Nine Months Ended March 31, 2025 December 31, 2024 Not Reliable - SEC Filing

THOMSON REUTERS
·
Sep 13, 2025

Benitec Biopharma Inc. Announces Non-Reliance on Previous Financial Statements Due to Share-Based Compensation Recording Errors

Reuters
·
Sep 13, 2025